Drug Search Results

Plitidepsin

Alternative Names: plitidepsin
Latest Update: 2024-12-06
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | European Medicines Agency | Ireland

Approved Indications: None

Known Adverse Events: None

Company: PharmaMar
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Plitidepsin

Countries in Clinic: Spain

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: COVID-19

Phase 2: Communicable Diseases

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
2022-002489-34	P2	Active, not recruiting	COVID-19	2024-02-03
E-APLICOV-PC	P2	Completed	COVID-19\|Communicable Diseases	2022-03-16
APL-D-003-20	P3	Active, not recruiting	COVID-19	2021-11-08
APLIDURG	P2	Not yet recruiting	COVID-19	2021-10-15	25%

Recent News Events

Date	Type	Title
05/14/2024	PubMed	Outcomes and clinical characteristics of the compassionate use of plitidepsin in COVID-19 patients with solid tumours, haematological malignancies or anti-CD20 antibody treatment.
04/25/2024	PubMed	The eEF1A protein in cancer: Clinical significance, oncogenic mechanisms, and targeted therapeutic strategies.
03/23/2024	PubMed	Marine-Derived Leads as Anticancer Candidates by Disrupting Hypoxic Signaling through Hypoxia-Inducible Factors Inhibition.
07/31/2023	News Article	GLOBAL SARCOMA THERAPY NOW LISTED ON PHARMACEUTICAL BENEFITS SCHEME
02/16/2023	News Article	GLOBAL SARCOMA THERAPY NOW APPROVED FOR NEW ZEALAND PATIENTS
10/25/2022	News Article	Understanding the Evolution of SARS-CoV-2 Could Be the Key to Treating It, According to Researchers at the UCSF QBI Coronavirus Research Group (QCRG)
01/11/2022	News Article	Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions